Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
Annemie Stege BojerMartin Heyn SørensenJenny BjerrePeter Haulund GaedeNiels VejlstrupPer Lav MadsenPublished in: Diabetes, obesity & metabolism (2021)
Short-term treatment with liraglutide did not improve left ventricular diastolic function, suggesting the cardioprotective effect is not exerted through the improvement in diastolic dysfunction.
Keyphrases
- left ventricular
- double blind
- hypertrophic cardiomyopathy
- acute myocardial infarction
- heart failure
- cardiac resynchronization therapy
- mitral valve
- oxidative stress
- ejection fraction
- left atrial
- clinical trial
- randomized controlled trial
- study protocol
- coronary artery disease
- percutaneous coronary intervention
- open label